IP Library › Assignment 053941/0491

Patent Assignment

Reel/Frame 053941/0491

Intellectual Property Security Agreement

Recorded: 2020-09-25 Pages: 119

View PDF Order Certified Copy

Assignor

AXSOME THERAPEUTICS, INC.

Executed: 2020-09-25

Assignee

HERCULES CAPITAL, INC., AS AGENT

400 HAMILTON AVENUE, SUITE 310, PALO ALTO, CALIFORNIA, 94301

Covered Properties (82)

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Application: 16/362,434 →

Publication: US US20200093760A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Application: 16/364,005 →

Publication: US US20190216800A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Application: 16/364,463 →

Publication: US US20190216801A1

Methods of Modulating Tetrabenazine Metabolites Plasma Levels Using Bupropion

Application: 16/513,367 →

Publication: US US20190374521A1

Compositions for Delivery of Reboxetine

Application: 16/514,948 →

Publication: US US20190381056A1

Combination of Meloxicam and Rizatriptan with Improved Pharmacokinetics

Application: 62/895,933 →

Combination of Meloxicam and Rizatriptan with Improved Pharmacokinetics

Application: 62/895,956 →

Use of Reboxetine to Treat Narcolepsy

Application: 62/943,077 →

Use of Reboxetine to Treat Narcolepsy

Application: 62/946,295 →

Combination treatment for migraine and other pain

Application: 62/955,905 →

Use of Esreboxetine to Treat Nervous System Disorders Such as Fibromyalgia

Application: 16/740,329 →

Publication: US US20200147093A1

Use of Reboxetine to Treat Narcolepsy

Patent: 11,351,175 →

Application: 16/740,409 →

Publication: US US20200147094A1

Use of Esreboxetine to Treat Nervous System Disorders Such as Fibromyalgia

Application: 16/740,410 →

Publication: US US20200147095A1

Use of Esreboxetine to Treat Nervous System Disorders Such as Fibromyalgia

Application: 16/740,411 →

Publication: US US20200147096A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Application: 62/971,174 →

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Application: 62/978,626 →

Pharmaceutical Compositions Comprising Meloxicam

Patent: 11,266,657 →

Application: 16/790,085 →

Publication: US US20200179396A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Application: 16/830,637 →

Publication: US US20200222339A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Patent: 11,344,513 →

Application: 16/806,145 →

Publication: US US20200197331A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Patent: 11,344,514 →

Application: 16/807,512 →

Publication: US US20200197333A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Patent: 11,331,285 →

Application: 16/832,153 →

Publication: US US20200222342A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Application: 62/992,060 →

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,821,181 →

Application: 16/841,436 →

Publication: US US20200230241A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,799,588 →

Application: 16/842,063 →

Publication: US US20200246461A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,894,053 →

Application: 16/854,320 →

Publication: US US20200261466A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,987,358 →

Application: 16/857,435 →

Publication: US US20200261467A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,821,182 →

Application: 16/867,929 →

Publication: US US20200276311A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Patent: 11,433,035 →

Application: 16/907,691 →

Publication: US US20200315992A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,933,136 →

Application: 16/927,623 →

Publication: US US20200338198A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,940,153 →

Application: 16/885,975 →

Publication: US US20200289524A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,905,693 →

Application: 16/921,006 →

Publication: US US20200330476A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Patent: 11,179,351 →

Application: 16/923,420 →

Publication: US US20200338021A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Patent: 11,179,352 →

Application: 16/924,510 →

Publication: US US20200345664A1

Methods of Modulating Tetrabenazine Metabolites Plasma Levels Using Bupropion

Application: 16/931,907 →

Publication: US US20200345663A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,918,722 →

Application: 16/997,740 →

Publication: US US20200376124A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,933,137 →

Application: 16/998,622 →

Publication: US US20200376125A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 9,821,075 →

Application: 15/132,130 →

Publication: US US20160228576A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,058,614 →

Application: 15/797,955 →

Publication: US US20180250407A9

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,029,010 →

Application: 15/902,770 →

Publication: US US20180207274A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,137,131 →

Application: 15/936,176 →

Publication: US US20180214380A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,265,399 →

Application: 15/984,055 →

Publication: US US20180264114A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,307,484 →

Application: 16/000,701 →

Publication: US US20180280512A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,265,400 →

Application: 15/988,104 →

Publication: US US20180264115A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,463,736 →

Application: 16/006,548 →

Publication: US US20180289806A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,369,224 →

Application: 16/006,642 →

Publication: US US20180289807A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,471,068 →

Application: 15/976,800 →

Publication: US US20180256593A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,195,279 →

Application: 15/989,734 →

Publication: US US20180271981A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,195,278 →

Application: 15/986,215 →

Publication: US US20190000975A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,369,225 →

Application: 16/006,692 →

Publication: US US20180289808A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,471,014 →

Application: 16/001,697 →

Publication: US US20180280306A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,583,088 →

Application: 16/002,865 →

Publication: US US20180280308A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,265,324 →

Application: 16/181,086 →

Publication: US US20190070192A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,322,181 →

Application: 16/247,406 →

Publication: US US20190142942A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,363,312 →

Application: 16/248,449 →

Publication: US US20190142943A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,471,069 →

Application: 16/374,081 →

Publication: US US20190231792A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,485,871 →

Application: 16/372,958 →

Publication: US US20190224320A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,426,839 →

Application: 16/372,977 →

Publication: US US20190224321A1

Combination Treatment for Migraine and Other Pain

Patent: 10,688,102 →

Application: 16/513,612 →

Publication: US US20190336510A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,456,471 →

Application: 16/403,034 →

Publication: US US20190255177A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,512,692 →

Application: 16/440,695 →

Publication: US US20190307884A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,512,693 →

Application: 16/454,319 →

Publication: US US20190314504A1

Dosage Forms and Methods for Enantiomerically Enriched or Pure Bupropion

Patent: 10,695,304 →

Application: 16/579,305 →

Publication: US US20200093761A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,532,101 →

Application: 16/565,111 →

Publication: US US20200000919A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,537,642 →

Application: 16/566,476 →

Publication: US US20200000920A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,517,950 →

Application: 16/567,859 →

Publication: US US20200000921A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,729,696 →

Application: 16/568,703 →

Publication: US US20200000819A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,729,697 →

Application: 16/570,451 →

Publication: US US20200000820A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,722,583 →

Application: 16/570,434 →

Publication: US US20200000922A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,729,773 →

Application: 16/572,042 →

Publication: US US20200009250A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,561,664 →

Application: 16/589,692 →

Publication: US US20200030338A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,583,144 →

Application: 16/653,877 →

Publication: US US20200038408A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,688,185 →

Application: 16/689,970 →

Publication: US US20200085952A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,695,429 →

Application: 16/690,464 →

Publication: US US20200085953A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,653,777 →

Application: 16/688,491 →

Publication: US US20200085951A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,695,430 →

Application: 16/693,052 →

Publication: US US20200085954A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,702,602 →

Application: 16/694,440 →

Publication: US US20200085955A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,702,535 →

Application: 16/773,567 →

Publication: US US20200155565A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,729,774 →

Application: 16/834,077 →

Publication: US US20200222539A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,758,617 →

Application: 16/835,848 →

Publication: US US20200230239A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,780,165 →

Application: 16/837,769 →

Publication: US US20200230240A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,758,618 →

Application: 16/843,490 →

Publication: US US20200246462A1

Pharmaceutical Compositions Comprising Meloxicam

Patent: 10,780,166 →

Application: 16/844,634 →

Publication: US US20200254097A1

Related Assignments (15)

Other recorded transfers of the patents in this record — the chain of ownership.

Assignment of Assignor's Interest Jun 25, 2019

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 049579/0708 →

Assignment of Assignor's Interest Jun 27, 2019

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 049613/0472 →

Assignment of Assignor's Interest Oct 3, 2019

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 050618/0971 →

Assignment of Assignor's Interest Mar 11, 2020

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 052089/0385 →

Assignment of Assignor's Interest Mar 12, 2020

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 052102/0337 →

Assignment of Assignor's Interest Apr 14, 2020

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 052395/0708 →

Assignment of Assignor's Interest May 28, 2020

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 052780/0458 →

Assignment of Assignor's Interest May 28, 2020

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 052775/0838 →

Assignment of Assignor's Interest May 28, 2020

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 052777/0841 →

Assignment of Assignor's Interest May 28, 2020

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 052778/0574 →

Assignment of Assignor's Interest May 28, 2020

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 052779/0001 →

Assignment of Assignor's Interest May 28, 2020

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 052780/0336 →

Assignment of Assignor's Interest Feb 9, 2021

From: TABUTEAU, HERRIOT

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 055189/0097 →

Security Interest May 9, 2025

From: AXSOME THERAPEUTICS, INC.; AXSOME MALTA LTD.

To: WILMINGTON TRUST, NATIONAL ASSOCIATION

Reel/Frame 071247/0836 →

Release of Security Interest May 22, 2025

From: HERCULES CAPITAL, INC.

To: AXSOME THERAPEUTICS, INC.

Reel/Frame 071337/0004 →